Seiji Takashio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5363521/publications.pdf

Version: 2024-02-01

414414 361413 1,442 114 20 32 citations h-index g-index papers 114 114 114 2171 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis. Circulation Journal, 2020, 84, 1610-1671.	1.6	98
2	Coronary Microvascular Dysfunction and Diastolic Load Correlate With Cardiac Troponin T Release Measured by a Highly Sensitive Assay in Patients With Nonischemic Heart Failure. Journal of the American College of Cardiology, 2013, 62, 632-640.	2.8	76
3	Growth Differentiation Factor-15 Is a Useful Prognostic Marker in Patients With Heart Failure With Preserved Ejection Fraction. Canadian Journal of Cardiology, 2014, 30, 338-344.	1.7	64
4	Significance of Low Plasma Levels of Brain-Derived Neurotrophic Factor in Patients With Heart Failure. American Journal of Cardiology, 2015, 116, 243-249.	1.6	57
5	Diagnostic utility of cardiac troponin T level in patients with cardiac amyloidosis. ESC Heart Failure, 2018, 5, 27-35.	3.1	56
6	Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention: a Kumamoto University Malignancy and Atherosclerosis (KUMA) study. European Heart Journal Quality of Care & Dinical Outcomes, 2018, 4, 290-300.	4.0	53
7	H2FPEF Score as a Prognostic Value in HFpEF Patients. American Journal of Hypertension, 2019, 32, 1082-1090.	2.0	50
8	Myocardial Late Iodine Enhancement and Extracellular Volume Quantification with Dual-Layer Spectral Detector Dual-Energy Cardiac CT. Radiology: Cardiothoracic Imaging, 2019, 1, e180003.	2.5	48
9	Non-invasive testing for sarcopenia predicts future cardiovascular events in patients with chronic kidney disease. International Journal of Cardiology, 2018, 268, 216-221.	1.7	45
10	Recent advances in diagnosis and treatment of cardiac amyloidosis. Journal of Cardiology, 2018, 71, 135-143.	1,9	39
11	Identification and Assessment of Cardiac Amyloidosis by Myocardial Strain Analysis of Cardiac Magnetic Resonance Imaging. Circulation Journal, 2017, 81, 1014-1021.	1.6	34
12	Combination of Commonly Examined Parameters Is a Useful Predictor of Positive ^{99 m} Tc-Labeled Pyrophosphate Scintigraphy Findings in Elderly Patients With Suspected Transthyretin Cardiac Amyloidosis. Circulation Journal, 2019, 83, 1698-1708.	1.6	33
13	Clinical characteristics and natural history of wildâ€ŧype transthyretin amyloid cardiomyopathy in Japan. ESC Heart Failure, 2020, 7, 2829-2837.	3.1	32
14	High serum levels of thrombospondin-2 correlate with poor prognosis of patients with heart failure with preserved ejection fraction. Heart and Vessels, 2016, 31, 52-59.	1,2	30
15	Trends in Diagnostic Imaging of Cardiac Amyloidosis: Emerging Knowledge and Concepts. Radiographics, 2020, 40, 961-981.	3.3	29
16	Usefulness of Sum of ST-Segment Elevation on Electrocardiograms (Limb Leads) for Predicting In-Hospital Complications in Patients With Stress (Takotsubo) Cardiomyopathy. American Journal of Cardiology, 2012, 109, 1651-1656.	1.6	26
17	Effect of Statins on Mortality in Heart Failure With Preserved Ejection Fraction Without Coronary Artery Diseaseã€ê― Report From the JASPER Study ―. Circulation Journal, 2019, 83, 357-367.	1.6	24
18	Myocardial Extracellular Volume Quantification Using Cardiac Computed Tomography: A Comparison of the Dual-energy Iodine Method and the Standard Subtraction Method. Academic Radiology, 2021, 28, e119-e126.	2.5	24

#	Article	IF	Citations
19	Imaging-guided PCI for event suppression in Japanese acute coronary syndrome patients: community-based observational cohort registry. Cardiovascular Intervention and Therapeutics, 2021, 36, 81-90.	2.3	24
20	Serum Potassium and Cardiovascular Events in Heart Failure With Preserved Left Ventricular Ejection Fraction Patients. American Journal of Hypertension, 2018, 31, 1098-1105.	2.0	22
21	Effects of the Mean Amplitude of Glycemic Excursions and Vascular Endothelial Dysfunction on Cardiovascular Events in Nondiabetic Patients With Coronary Artery Disease. Journal of the American Heart Association, 2017, 6, .	3.7	21
22	Correlation Between Extent of Myocardial Fibrosis Assessed by Cardiac Magnetic Resonance and Cardiac Troponin T Release in Patients With Nonischemic Heart Failure. American Journal of Cardiology, 2014, 113, 1697-1704.	1.6	19
23	Temporal trends in coronary intervention strategies and the impact on one-year clinical events: data from a Japanese multi-center real-world cohort study. Cardiovascular Intervention and Therapeutics, 2022, 37, 66-77.	2.3	19
24	Myocardial extracellular volume quantification in cardiac CT: comparison of the effects of two different iterative reconstruction algorithms with MRI as a reference standard. European Radiology, 2020, 30, 691-701.	4.5	18
25	Diagnostic and Prognostic Value of Subcutaneous Tissue Biopsy in Patients With Cardiac Amyloidosis. American Journal of Cardiology, 2012, 110, 1507-1511.	1.6	17
26	Cardiovascular magnetic resonance myocardial T1 mapping to detect and quantify cardiac involvement in familial amyloid polyneuropathy. European Radiology, 2017, 27, 4631-4638.	4.5	17
27	Prognostic Value of the CHADS ₂ Score for Adverse Cardiovascular Events in Coronary Artery Disease Patients Without Atrial Fibrillation—A Multi enter Observational Cohort Study. Journal of the American Heart Association, 2017, 6, .	3.7	17
28	Quantification of Myocardial Extracellular Volume With Planning Computed Tomography for Transcatheter Aortic Valve Replacement to Identify Occult Cardiac Amyloidosis in Patients With Severe Aortic Stenosis. Circulation: Cardiovascular Imaging, 2020, 13, e010358.	2.6	17
29	Total Thrombus-Formation Analysis System can Predict 1-Year Bleeding Events in Patients with Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 2020, 27, 215-225.	2.0	16
30	H 2 FPEF score for predicting future heart failure in stable outpatients with cardiovascular risk factors. ESC Heart Failure, 2020, 7, 66-75.	3.1	16
31	Optical Coherence Tomography-Guided Percutaneous Coronary Intervention With Low-Molecular-Weight Dextran ― Effect on Renal Function ―. Circulation Journal, 2020, 84, 917-925.	1.6	14
32	HE4 Predicts Progressive Fibrosis and Cardiovascular Events in Patients With Dilated Cardiomyopathy. Journal of the American Heart Association, 2021, 10, e021069.	3.7	14
33	Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H1409-H1415.	3.2	12
34	Prognostic significance of polyvascular disease in heart failure with preserved left ventricular ejection fraction. Medicine (United States), 2019, 98, e15959.	1.0	12
35	Nonâ€Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis. ESC Heart Failure, 2019, 6, 122-130.	3.1	12
36	Correlation between microvascular dysfunction and B-type natriuretic peptide levels in non-ischemic heart failure patients with cardiac fibrosis. International Journal of Cardiology, 2017, 228, 881-885.	1.7	11

#	Article	lF	CITATIONS
37	Myocardial extracellular volume quantification using CT for the identification of occult cardiac amyloidosis in patients with severe aortic stenosis referred for transcatheter aortic valve replacement. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 97-98.	3.0	11
38	Clinical Significance of Brachial-Ankle Pulse Wave Velocity in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction. American Journal of Hypertension, 2019, 32, 657-667.	2.0	11
39	Cardioprotective Effects of Rivaroxaban on Cardiac Remodeling After Experimental Myocardial Infarction in Mice. Circulation Reports, 2020, 2, 158-166.	1.0	10
40	HFA-PEFF scores: prognostic value in heart failure with preserved left ventricular ejection fraction. Korean Journal of Internal Medicine, 2022, 37, 96-108.	1.7	10
41	CYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular angina. IJC Heart and Vasculature, 2017, 15, 15-20.	1.1	9
42	Clinical Features of Disaster-Related Deaths After the Kumamoto Earthquake 2016 ― Comparison With the Great East Japan Earthquake 2011 ―. Circulation Reports, 2019, 1, 531-533.	1.0	9
43	The controlling nutritional status score predicts outcomes of cardiovascular events in patients with heart failure with preserved ejection fraction. IJC Heart and Vasculature, 2020, 29, 100563.	1.1	9
44	Usefulness of relative apical longitudinal strain index to predict positive ^{99m} Tcâ€labeled pyrophosphate scintigraphy findings in advancedâ€age patients with suspected transthyretin amyloid cardiomyopathy. Echocardiography, 2020, 37, 1774-1783.	0.9	9
45	Development and assessment of total thrombus-formation analysis system-based bleeding risk model in patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2021, 325, 121-126.	1.7	9
46	Clinical significance of reactive oxidative metabolites in patients with heart failure with reduced left ventricular ejection fraction. Journal of Cardiac Failure, 2021, 27, 57-66.	1.7	9
47	Prognostic significance of liver stiffness assessed by fibrosisâ€4 index in patients with heart failure. ESC Heart Failure, 2021, 8, 3809-3821.	3.1	9
48	Prognostic value of left atrial strain in patients with wildâ€type transthyretin amyloid cardiomyopathy. ESC Heart Failure, 2021, 8, 5316-5326.	3.1	9
49	Late iodine enhancement and myocardial extracellular volume quantification in cardiac amyloidosis by using dual-energy cardiac computed tomography performed on a dual-layer spectral detector scanner. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official lournal of the International Society of Amyloidosis, 2018, 25, 137-138.	3.0	8
50	Late gadolinium enhancement on cardiac magnetic resonance imaging is associated with coronary endothelial dysfunction in patients with dilated cardiomyopathy. Heart and Vessels, 2018, 33, 393-402.	1.2	8
51	Detection of acquired von Willebrand syndrome after ventricular assist device by total thrombusâ€formation analysis system. ESC Heart Failure, 2020, 7, 3235-3239.	3.1	8
52	A simple method of sarcopenia detection can predict adverse cardiovascular events in patients with abdominal obesity. International Journal of Obesity, 2021, 45, 2214-2220.	3.4	8
53	Sex-related differences in the clinical characteristics of wild-type transthyretin amyloidosis cardiomyopathy. Journal of Cardiology, 2022, 79, 50-57.	1.9	8
54	Myocardial extracellular volume quantification by cardiac CT in pulmonary hypertension: Comparison with cardiac MRI. European Journal of Radiology, 2022, 153, 110386.	2.6	8

#	Article	IF	CITATIONS
55	Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an <i>LDL Receptor</i> Mutation and a <i>PCSK9</i> V4I Mutation. Internal Medicine, 2018, 57, 3551-3557.	0.7	7
56	Prognostic impact of the presence of on-duty cardiologist on patients with acute myocardial infarction admitted during off-hours. Journal of Cardiology, 2020, 76, 184-190.	1.9	7
57	A Randomized, Double-Blind Comparison Study of Royal Jelly to Augment Vascular Endothelial Function in Healthy Volunteers. Journal of Atherosclerosis and Thrombosis, 2022, 29, 1285-1294.	2.0	7
58	Correlation of left ventricular dyssynchrony on gated myocardial perfusion SPECT analysis with extent of late gadolinium enhancement on cardiac magnetic resonance imaging in hypertrophic cardiomyopathy. Heart and Vessels, 2018, 33, 623-629.	1.2	6
59	Utility of Single-Photon Emission Computed Tomography/Computed Tomography Fusion Imaging With ^{99 m} Tc-Pyrophosphate Scintigraphy in the Assessment of Cardiac Transthyretin Amyloidosis. Circulation Journal, 2018, 82, 1970-1971.	1.6	6
60	Hemodialysis-related low thrombogenicity measured by total thrombus-formation analysis system in patients undergoing percutaneous coronary intervention Thrombosis Research, 2021, 200, 141-148.	1.7	6
61	Myocardial Tissue Characterization by Combining Extracellular Volume Fraction and T2 Mapping. JACC: Cardiovascular Imaging, 2022, 15, 700-704.	5.3	6
62	Utility of left atrial and ventricular strain for diagnosis of transthyretin amyloid cardiomyopathy in aortic stenosis. ESC Heart Failure, 2022, 9, 1976-1986.	3.1	6
63	Successful treatment of deep vein thrombosis caused by iliac vein compression syndrome with a single-dose direct oral anti-coagulant. Thrombosis Journal, 2017, 15, 4.	2.1	5
64	Elongation of the high right atrium to coronary sinus conduction time predicts the recurrence of atrial fibrillation after radiofrequency catheter ablation. International Journal of Cardiology, 2020, 300, 147-153.	1.7	5
65	Clinical significance of diastolic late mitral annular velocity in heart failure with preserved ejection fraction. International Journal of Cardiology, 2020, 316, 145-151.	1.7	5
66	Increased soluble programed cell death-ligand 1 is associated with acute coronary syndrome. International Journal of Cardiology, 2022, 349, 1-6.	1.7	5
67	A simple staging system using biomarkers for wildâ€ŧype transthyretin amyloid cardiomyopathy in Japan. ESC Heart Failure, 2022, 9, 1731-1739.	3.1	5
68	Late gadolinium enhancement on cardiac magnetic resonance predicts coronary vasomotor abnormality and myocardial lactate production in patients with chronic heart failure. Heart and Vessels, 2016, 31, 1969-1979.	1.2	4
69	Accumulation of coronary risk factors is associated with progression of mitral annular calcification in patients undergoing dialysis therapy: A long-term follow-up study. International Journal of Cardiology, 2019, 293, 248-253.	1.7	4
70	Efficacy of Cardiac Rehabilitation in Heart Failure Patients With Low Body Mass Index. Circulation Journal, 2019, 83, 334-341.	1.6	4
71	Leftâ€dominant arrhythmogenic cardiomyopathy with a nonsense mutation in <scp><i>DSP</i></scp> . ESC Heart Failure, 2020, 7, 3174-3178.	3.1	4
72	Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. Cardiovascular Intervention and Therapeutics, 2022, 37, 60-65.	2.3	4

#	Article	IF	CITATIONS
73	Role of Noninvasive Diagnostic Imaging in Cardiac Amyloidosis: A Review. Cardiovascular Imaging Asia, 2018, 2, 97.	0.1	4
74	Wild-type transthyretin amyloid cardiomyopathy complicated by spinal canal stenosis, carpal tunnel syndrome, and rotator cuff tears: a case report. European Heart Journal - Case Reports, 2020, 4, 1-6.	0.6	4
75	Incidence, clinical characteristics, and diagnostic approach in transthyretin amyloid cardiomyopathy: The Kumamoto Cardiac Amyloidosis Survey. Journal of Cardiology, 2022, 80, 49-55.	1.9	4
76	Malnutrition-associated high bleeding risk with low thrombogenicity in patients undergoing percutaneous coronary intervention. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1227-1235.	2.6	4
77	Extracardiac Biopsy Sensitivity in Transthyretin Amyloidosis Cardiomyopathy Patients With Positive ^{99 m} Tc-Labeled Pyrophosphate Scintigraphy Findings. Circulation Journal, 2022, 86, 1113-1120.	1.6	4
78	Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wildâ \in Type Transthyretin Amyloid Cardiomyopathy. Journal of the American Heart Association, 2022, 11 , .	3.7	4
79	Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy. Heart and Vessels, 2017, 32, 708-713.	1.2	3
80	Reduction in thrombogenic activity and thrombocytopenia after transcatheter aortic valve implantation $\hat{a} \in \text{``The ATTRACTIVE-TTAS}$ study. IJC Heart and Vasculature, 2019, 23, 100346.	1.1	3
81	Doubleâ€chambered right ventricle complicated by hypertrophic obstructive cardiomyopathy diagnosed as Noonan syndrome. ESC Heart Failure, 2020, 7, 721-726.	3.1	3
82	Plasma growth differentiation factor 15: a novel tool to detect early changes of hereditary transthyretin amyloidosis. ESC Heart Failure, 2021, 8, 1178-1185.	3.1	3
83	Usefulness of quantitative 99mTc-pyrophosphate SPECT/CT for predicting the prognosis of patients with wild-type transthyretin cardiac amyloidosis. Japanese Journal of Radiology, 2022, 40, 508-517.	2.4	3
84	Cardiac computed tomographyâ€derived myocardial tissue characterization after anthracycline treatment. ESC Heart Failure, 2022, 9, 1792-1800.	3.1	3
85	Prognostic value of right ventricular global longitudinal strain in transthyretin amyloid cardiomyopathy. Journal of Cardiology, 2022, 80, 56-63.	1.9	3
86	Analysis for the primary predictive factor for the incidence of esophageal injury after ablation of atrial fibrillation. Journal of Cardiology, 2018, 72, 480-487.	1.9	2
87	Cytotoxin-associated gene-A-seropositivity and Interleukin-1 polymorphisms influence adverse cardiovascular events. IJC Heart and Vasculature, 2020, 27, 100498.	1.1	2
88	Temporal Trends in Atherosclerotic Risk Factors in School Children ― Findings From 20-Year Surveillance ―. Circulation Journal, 2020, 84, 524-528.	1.6	2
89	Identification of Wild-Type Transthyretin Cardiac Amyloidosis by Quantifying Myocardial Extracellular Volume Using Cardiac Computed Tomography in Atrial Arrhythmias. Circulation: Cardiovascular Imaging, 2020, 13, e010261.	2.6	2
90	Impact of cerebrovascular comorbidity on prognosis in Japanese patients undergoing PCI: 1-year data from Japanese multicenter registry (KICS). Heart and Vessels, 2022, , 1.	1.2	2

#	Article	IF	Citations
91	Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma. British Journal of Haematology, 2022, 198, .	2.5	2
92	Clinical potential of dual-energy cardiac CT in cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 91-92.	3.0	1
93	A case of repetitive acute coronary syndrome in a patient with familial hypercholesterolemia. Journal of Cardiology Cases, 2019, 20, 200-204.	0.5	1
94	Coronary blood flow volume change is negatively associated with platelet aggregability in patients with non-obstructive ischemic heart disease who have no anti-platelet agents. International Journal of Cardiology, 2019, 277, 3-7.	1.7	1
95	Analysis of the driving mechanism in paroxysmal atrial fibrillation: comparison of the activation sequence between the left atrial body and pulmonary vein. Journal of Cardiology, 2020, 75, 673-681.	1.9	1
96	Comparison of electron microscopic findings and clinical presentation in three patients with mitochondrial cardiomyopathy caused by the mitochondrial DNA mutation m.3243A > G. Medical Molecular Morphology, 2021, 54, 181-186.	1.0	1
97	Histogram features of Fabry disease with pseudonormalization in native T1 mapping. European Heart Journal Cardiovascular Imaging, 2021, 22, e23-e23.	1.2	1
98	Assessment of cardiac implantable electric device lead perforation using a metal artifact reduction algorithm in cardiac computed tomography. European Journal of Radiology, 2021, 136, 109530.	2.6	1
99	Elevated C-reactive protein is significantly associated with left ventricular dysfunction in patients with aortic regurgitation and concomitant collagen disease. International Journal of Cardiology, 2021, 328, 152-157.	1.7	1
100	Dynamic evaluation of myocardial extracellular volume fraction using dual-layer spectral detector computed tomography. European Heart Journal - Case Reports, 2020, 4, 1-2.	0.6	1
101	Multiple focal atrial tachycardia as a characteristic finding of intractable arrhythmia associated with wild-type transthyretin amyloid cardiomyopathy. HeartRhythm Case Reports, 2022, , .	0.4	1
102	Increased thrombogenicity is associated with revascularization outcomes in patients with chronic limb-threatening ischemia. Journal of Vascular Surgery, 2022, 76, 513-522.e3.	1.1	1
103	Repetitive early stent thrombosis in a patient with the CYP2C19*3/*3 genotype. Journal of Cardiology Cases, 2011, 4, e16-e19.	0.5	0
104	A case of human immunodeficiency virus-related heart failure resembling dilated cardiomyopathy but accompanied by high cardiac output. Journal of Cardiology Cases, 2014, 10, 167-170.	0.5	0
105	When Is the Optimal Timing of Surgical Intervention for Severe Functional Tricuspid Regurgitation?. Case Reports in Cardiology, 2017, 2017, 1-4.	0.2	0
106	Transthyretin Amyloid Cardiomyopathy Diagnosed on Incidental Myocardial Uptake During Bone Scintigraphy. Circulation Journal, 2020, 84, 679.	1.6	0
107	Utility of Kumamoto Criteria in Diagnosing Transthyretin Cardiac Amyloidosis in Real-World Practiceã€êê€ Reply ―. Circulation Journal, 2020, 84, 681-682.	1.6	0
108	Preclinical diagnosis of wild-type transthyretin amyloid cardiomyopathy in a patient undergoing carpal tunnel release. Journal of Cardiology Cases, 2021, 24, 250-253.	0.5	0

#	Article	IF	CITATIONS
109	Temporal Change in Longitudinal Strain After Domino Liver Transplantation With Liver Grafts Explanted From Patients With Hereditary Amyloidogenic Transthyretin Amyloidosis. Circulation Reports, 2020, 2, 730-738.	1.0	O
110	Extensive Loss of Myocardium due to Lymphocytic Fulminant Myocarditis: An Autopsy Case Report of a Patient with Persistent Cardiac Arrest for 25 Days. Internal Medicine, 2020, 59, 3171-3175.	0.7	0
111	Dynamic evaluation of myocardial extracellular volume fraction using dual-layer spectral detector computed tomography. European Heart Journal - Case Reports, 2020, 4, 1-2.	0.6	O
112	Can myocardial susceptibility quantification be an imaging biomarker for cardiac amyloidosis?. Japanese Journal of Radiology, 2021, , 1.	2.4	0
113	Dynamic change of mitral regurgitation after myocardial reverse remodelling: a case report. European Heart Journal - Case Reports, 2022, 6, ytac110.	0.6	O
114	Abstract 10841: Clinical Significance of Left Atrial Function Estimated by Two Dimensional Speckle Tracking Echocardiography for Diagnosis of Concomitant Transthyretin Amyloid Cardiomyopathy in Patients with Aortic Stenosis. Circulation, 2021, 144, .	1.6	0